{
    "total": 3,
    "articles": [{
        "title": "Abbvie Announces New Phase 3B Results in Genotype 1B Chronic Hepatitis C Patients with Compensated Liver Cirrhosis",
        "link": "http://www.drugs.com/clinical_trials/abbvie-announces-new-phase-3b-results-genotype-1b-chronic-hepatitis-c-patients-compensated-liver-16861.html?utm_source=ddc&utm_medium=rss&utm_campaign=Abbvie+Announces+New+Phase+3B+Results+in+Genotype+1B+Chronic+Hepatitis+C+Patients+with+Compensated+Liver+Cirrhosis",
        "description": "NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment...",
        "pubDate": "Thu, 25 Jun 2015 02:06:22 GMT"
    }, {
        "title": "Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with IBS with Constipation",
        "link": "http://www.drugs.com/clinical_trials/synergy-pharmaceuticals-initiates-second-phase-3-clinical-trial-plecanatide-patients-ibs-16858.html?utm_source=ddc&utm_medium=rss&utm_campaign=Synergy+Pharmaceuticals+Initiates+Second+Phase+3+Clinical+Trial+of+Plecanatide+in+Patients+with+IBS+with+Constipation",
        "description": "NEW YORK, June 23, 2015 -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0...",
        "pubDate": "Wed, 24 Jun 2015 00:06:57 GMT"
    }, {
        "title": "Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections",
        "link": "http://www.drugs.com/clinical_trials/paratek-doses-first-patient-phase-3-clinical-trial-omadacycline-acute-bacterial-skin-skin-structure-16857.html?utm_source=ddc&utm_medium=rss&utm_campaign=Paratek+Doses+First+Patient+in+Phase+3+Clinical+Trial+of+Omadacycline+in+Acute+Bacterial+Skin+and+Skin+Structure+Infections",
        "description": "BOSTON, June 23, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry today announced the dosing...",
        "pubDate": "Tue, 23 Jun 2015 23:06:23 GMT"
    }]
}